Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside

11 Aug 2022

Abstract excerpt

DNA damage repair (DDR) defects are common in different cancer types, and these alterations can be exploited therapeutically. Epithelial ovarian cancer (EOC) is among the tumours with the highest percentage of hereditary cases. BRCA1 and BRCA2 predisposing pathogenic variants (PVs) were the first to be associated with EOC, whereas additional genes comprising the homologous recombination (HR) pathway have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36010882
DOI: 10.3390/cancers14163888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA Mutations in Ovarian and Prostate Cancer: Bench to BedsidePMID 36010882Read ↗

Defective DNA repair mechanisms in prostate cancer: impact of olaparibSemantic proximity Read ↗

PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCASemantic proximity Read ↗

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.Semantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

PARP Inhibitors in Prostate Cancer.Semantic proximity Read ↗

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read ↗

Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic OpportunitiesSemantic proximity Read ↗

Roles of the PARP Inhibitor in BRCA1 and BRCA2 Pathogenic Mutated Metastatic Prostate Cancer: Direct Functions and Modification of the Tumor MicroenvironmentSemantic proximity Read ↗

Targeting DNA RepairSemantic proximity Read ↗

BRCA2 and Other DDR Genes in Prostate CancerSemantic proximity Read ↗

DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic OpportunitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.